Source comparison
Peptides for Rheumatoid Arthritis Compared: BPC-157 vs TB-500 Clinical Relevance
BPC-157 Nitric oxide stabilisation, TNF-α and IL-1β suppression, cytoprotection at inflamed sites 50–65% reduction in synovial inflammation and joint swelling in rodent adjuvant-induced arthritis models; reduced cartilage degradation markers 10–20 mcg/kg daily
This comparison does not assign a generated winner or score.
- BPC-157
- Nitric oxide stabilisation, TNF-α and IL-1β suppression, cytoprotection at inflamed sites
- 50–65% reduction in synovial inflammation and joint swelling in rodent adjuvant-induced arthritis models; reduced cartilage degradation markers
- 10–20 mcg/kg daily (research reference)
- Subcutaneous injection near affected joint or intraperitoneal
- Approximately 4–6 hours (requires daily dosing)
- 4/5. Strong anti-inflammatory mechanism aligned with early-stage RA cytokine pathology; daily administration required; not FDA-approved for human use
- TB-500
- Actin polymerisation, vascular endothelial growth factor upregulation, cell migration and angiogenesis
- Accelerated tendon and ligament repair in equine models; increased collagen deposition and reduced lameness in joint injury studies; promotes tissue remodelling post-inflammation
- 2.0–2.5 mg twice weekly for 4 weeks, then 2.0 mg weekly maintenance (research reference)
- Subcutaneous injection (systemic)
- 5–7 days (allows less frequent dosing)
- 3.5/5. Regenerative mechanism suited for structural tissue repair rather than active inflammation suppression; longer dosing interval; best used after acute inflammatory phase resolves
- Combined Protocol (BPC-157 + TB-500)
- Dual-phase approach: cytokine suppression during active flare + tissue repair during recovery phase
- No direct head-to-head trials; combined protocols used in research settings based on complementary mechanisms
- BPC-157 daily during inflammation + TB-500 twice weekly during repair phase
- Subcutaneous for both
- N/A (staggered administration)
- 4.5/5. Mechanistically rational for sequential use in early RA (inflammation control) followed by late RA (structural repair); requires understanding of disease stage; highest complexity and cost